Abstract
Background The best curative treatment for hepatocellular carcinoma (HCC) is liver transplant (LT), but the limited number of organs available for LT dictates strict eligibility criteria. Despite this patient selection stringency, current criteria often fail in pinpointing patients at risk of HCC relapse and in identifying good prognosis patients that could benefit from a LT. HepatoPredict kit was developed and clinically validated to forecast the benefit of LT in patients diagnosed with HCC. By combining clinical variables and a gene expression signature in an ensemble of machine learning algorithms, HepatoPredict stratifies HCC patients according to their risk of relapse after LT.
Methods Aiming at the characterization of the analytical performance of HepatoPredict kit in terms of sensitivity, specificity and robustness, several variables were tested which included reproducibility between operators and between RNA extractions and RT-qPCR runs, interference of input RNA levels or varying reagent levels. The described methodologies, included in the HepatoPredict kit, were tested according to analytical validation criteria of multi-target genomic assays described in guidelines such as ISO201395-2019, MIQE, CLSI-MM16, CLSI-MM17, and CLSI-EP17-A. Furthermore, a new retrained version of the HepatoPredict algorithms is also presented and tested.
Results The results of the analytical performance demonstrated that the HepatoPredict kit performed within the required levels of robustness (p > 0.05), analytical specificity (inclusivity ≥ 95 %), and sensitivity (LoB, LoD, linear range, and amplification efficiency between 90 – 110 %). The introduced operator, equipment, input RNA and reagents into the assay had no significant impact on HepatoPredict classifier results. As demonstrated in a previous clinical validation, a new retrained version of the HepatoPredict algorithm still outperformed current clinical criteria, in the accurate identification of HCC patients that more likely will benefit from a LT.
Conclusions Despite the variations in the molecular and clinical variables, the prognostic information obtained with HepatoPredict kit and does not change and can accurately identify HCC patients more likely to benefit from a LT. HepatoPredict performance robustness also validates its easy integration into standard diagnostic laboratories.
Competing Interest Statement
The work described here is subject to patent WO 2021/064230 A1; JPL, JC, and HPM declare an ownership interest in the company Ophiomics. MGR, DP, LPF, and JLN are employees at Ophiomics. SS has no competing interests.
Funding Statement
This study was partly funded by a grant from the European Innovation Council under the EIC Accelerator scheme (Contract number: 946364).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics authorities (Comissao de Etica para a Saude) from the Centro Hospitalar de Lisboa Central (Process number 144/2014) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
List of Abbreviations
- AFP:
- alpha-fetoprotein
- DNA:
- Deoxyribonucleic acid
- CI:
- Confidence interval
- CLSI:
- Clinical laboratory standards institute
- Cq:
- Cycle threshold
- DCP:
- des-γ carboxyprothrombin
- FFPE:
- formalin-fixed paraffin-embedded
- gDNA:
- Genomic DNA
- HBV:
- Hepatitis B virus
- HCC:
- Hepatocellular carcinoma
- HCV:
- Hepatitis C virus
- ISO:
- International organization for standardization
- LoB:
- Limit of blank
- LoD:
- Limit of detection
- LT:
- Liver transplantation
- MIQE:
- Minimum information for publication of quantitative real-time PCR experiments
- NPV:
- Negative predictive value
- NTC:
- No template control
- N/A:
- Not applied
- p:
- p-value
- RNA:
- Ribonucleic acid
- RT-qPCR:
- real-time quantitative reverse transcription polymerase chain reaction
- SD:
- Standard deviation
- STD:
- Standard
- TTV:
- Total tumor volume
- UCSF:
- University of California San Francisco
